Review highlights role of organ-specific aging clocks in cardiovascular geroscience trials

A review published in Herz highlights how recently developed organ- and cell-specific aging clocks can estimate the biological age of the cardiovascular system, potentially serving as surrogate outcomes to facilitate human geroscience trials.

Researchers from the Technical University of Munich published a review discussing biological aging as a modifiable risk factor for cardiovascular disease.

The authors reported that while translating animal lifespan extension results to humans is challenging due to long lifespans, the development of molecular, functional, and imaging-based 'aging clocks' provides a surrogate method to estimate the rate of biological aging.

The paper highlighted recently developed organ- and cell-specific aging clocks that estimate the biological age of the heart, vasculature, and specific cardiovascular cell types as promising tools for cardiovascular risk prediction and clinical trial surrogacy.

Cardiovascular disease is the strongest age-associated pathology, making the heart and vasculature primary targets for systemic and localized geroscience therapies.

By utilizing organ-specific surrogate outcomes, clinical researchers can evaluate the efficacy of anti-aging interventions such as caloric restriction, rapamycin, taurine, or plasma exchange without waiting decades for hard clinical endpoints like mortality.

An shift toward validated, organ-specific aging clocks could lower clinical development barriers for biotech firms targeting age-related cardiovascular dysfunction.

Regulatory acceptance of biological age surrogate markers remains a critical factor, but positive research consensus supports the groundwork for future clinical trial designs utilizing these metrics.

The initiation of human geroscience trials that utilize cardiac- or vasculature-specific epigenetic and cellular clocks as primary or secondary surrogate endpoints.